Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Clare, Okines"'
Autor:
Dennis J. Slamon, Frances Valdes, Gail S. Wright, Elisavet Paplomata, Timothy J. Pluard, Erik Jakobsen, Xiaofu Zhu, Alison Conlin, Alicia Frances Clare Okines, Arlene Chan, Amy S. Clark, Stephanie Sutherland, Erika Hamilton, Ian E. Krop, Tanya A. Wahl, Grace An, Karen A. Gelmon, Jennifer M. Specht, Jorge Ramos, Maryam B. Lustberg
Publikováno v:
Okines, A F C, Paplomata, E, Wahl, T A, Wright, G L S, Sutherland, S, Jakobsen, E, Valdes, F, Chan, A, Clark, A S, Conlin, A K, Lustberg, M B, Specht, J M, Pluard, T J, Zhu, X, Krop, I E, Gelmon, K A, Slamon, D J, Ramos, J, An, G & Hamilton, E P 2020, ' Management of adverse events in patients with HER2+metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB) ', Journal of Clinical Oncology, vol. 38, no. Suppl. 15, 1043 . https://doi.org/10.1200/JCO.2020.38.15_suppl.1043
1043 Background: Tucatinib (TUC) is an investigational TKI, highly selective for HER2 without significant inhibition of EGFR. HER2CLIMB is a randomized trial of TUC vs placebo in combination with trastuzumab and capecitabine in patients (pts) with HE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64cdacc29f6d6736d7139f156136b874
https://portal.findresearcher.sdu.dk/da/publications/772ee6e3-47ed-4204-ade5-d9f3fc863cd6
https://portal.findresearcher.sdu.dk/da/publications/772ee6e3-47ed-4204-ade5-d9f3fc863cd6
Autor:
Tanios Bekaii-Saab, Paula R. Pohlmann, Evan Y. Yu, Luke Walker, Bradley J. Monk, Vicky Kang, Yoshiaki Nakamura, Martin Reck, Alicia Frances Clare Okines, David M. O'Malley, Tom Stinchcombe
Publikováno v:
Journal of Clinical Oncology. 39:TPS3151-TPS3151
TPS3151 Background: Tucatinib (TUC) is a highly selective HER2-directed TKI approved in combination with trastuzumab (Tras) and capecitabine (Cape) for HER2 overexpressed/amplified (HER2+) metastatic breast cancer (BC), based on a statistically signi
Autor:
Dennis J. Slamon, Jorge Ramos, Eric P. Winer, Volkmar Mueller, Virginia F. Borges, Chiyu Zhang, Erika Hamilton, Rashmi Krishna Murthy, Gabriel N. Hortobagyi, Sherene Loi, Ian E. Krop, Alicia Frances Clare Okines, Giuseppe Curigliano, Karen A. Gelmon, Lisa A. Carey, Sibylle Loibl, Sara A. Hurvitz, David Cameron, Elisavet Paplomata, Mark D. Pegram
Publikováno v:
Journal of Clinical Oncology. 39:1043-1043
1043 Background: Tucatinib (TUC) is an oral tyrosine kinase inhibitor (TKI) highly specific for HER2. TUC is approved for use in combination with trastuzumab (T) and capecitabine (C) in patients (pts) with and without brain metastases (BM) who have r
Autor:
Tom, Waddell, Ian, Chau, David, Cunningham, David, Gonzalez, Alicia Frances Clare, Okines, Alicia, Frances, Clare, Okines, Andrew, Wotherspoon, Claire, Saffery, Gary, Middleton, Jonathan, Wadsley, David, Ferry, Wasat, Mansoor, Tom, Crosby, Fareeda, Coxon, David, Smith, Justin, Waters, Timothy, Iveson, Stephen, Falk, Sarah, Slater, Clare, Peckitt, Yolanda, Barbachano
Publikováno v:
BASE-Bielefeld Academic Search Engine
The Lancet Oncology
The Lancet Oncology
Summary Background EGFR overexpression occurs in 27–55% of oesophagogastric adenocarcinomas, and correlates with poor prognosis. We aimed to assess addition of the anti-EGFR antibody panitumumab to epirubicin, oxaliplatin, and capecitabine (EOC) in
Autor:
Ravindhi Murphy, Michael Flynn, Apostolos Konstantis, Elena Takeuchi, Benjamin Sanderson, Fharat Raja, Rebecca Roylance, Farah Rehman, Amy Elizabeth Guppy, Daire Hanna, Emma Spurrell, Karim Keshwani, anna lerner, Elizabeth Sharkey, Charlotte Westbury, Alicia Frances Clare Okines, Ruth E. Board, Judy King
Publikováno v:
Journal of Clinical Oncology. 37:e12525-e12525
e12525 Background: Fulvestrant is a selective oestrogen receptor (ER) down regulator used to treat hormone receptor-positive advanced breast cancer in postmenopausal women. It is used at various time points in treatment. However, variations in fundin
Autor:
Iain R. Macpherson, Paula Proszek, Jenny King, Andrew Dodson, Javier Pascual, Emma Hall, Hannah Bye, Mona Parmar, Nicholas C. Turner, Juanita Lopez, Alison Turner, Isaac Garcia-Murillas, Alicia Frances Clare Okines, Laura Finneran, Alistair Ring, Sarah Emily Ward, Anne C Armstrong
Publikováno v:
Journal of Clinical Oncology. 37:1051-1051
1051 Background: PI3K and CDK4/6 inhibitors synergise in ER+ve and –ve PIK3CA-mt breast cancer (BC) models. Escalation phase of this study set recommended phase 2 dose (RP2D) at P 125mg on a 3/1 scheme plus T 2mg daily ( Lim, ASCO 2017). Here we pr
Autor:
Matthew Nankivell, Sanna Hulkki Wilson, Andrew Wotherspoon, Ruth E Langley, David Cunningham, David Gonzalez de Castro, Alicia Frances Clare Okines, Clare Peckitt, Elizabeth C Smyth, Zakaria Eltahir
Publikováno v:
Journal of Clinical Oncology. 34:4064-4064
4064Background: MMRd and MSI are prognostic for survival in many cancers and predict resistance to fluoropyrimidines in colon cancer. We examined the relationship between MMRd, MSI and survival in ...
Autor:
D Alderson, Richard Krysztopik, Heike I. Grabsch, M Griffin, Rupert Langer, Cindy Goldstein, Fareeda Y. Coxon, Stephen Falk, David Cunningham, S. P. Stenning, Susan Pritchard, Adrian Crellin, Matthew Nankivell, Joyce Thompson, Alicia Frances Clare Okines, Ruth E Langley, Jane M Blazeby
Publikováno v:
Journal of Clinical Oncology. 33:4002-4002
4002 Background: Neoadjuvant chemotherapy (2 cycles cisplatin/5 fluorouracil) (CF) followed by surgery is a standard of care for locally advanced oesophageal cancer. We investigated whether more ch...
Autor:
Andrew Wotherspoon, Sanna Hulkki Wilson, Matthew Nankivell, Ruth E Langley, Alicia Frances Clare Okines, Elizabeth C Smyth, David Cunningham, David Gonzalez de Castro, Sally P. Stenning
Publikováno v:
Journal of Clinical Oncology. 33:71-71
71 Background: In oesophagogastric cancer TP53 mutation may be prognostic and/or predict for chemoresistance, however available data are conflicting. We hypothesised that TP53 status would impact on survival for patients (pts) randomised to surgery a
Autor:
Alicia Frances Clare Okines, Matthew Nankivell, Andrew Wotherspoon, Elizabeth C Smyth, David Cunningham, Ruth E Langley, David Gonzalez de Castro, Sally P. Stenning, Sanna Hulkki Wilson
Publikováno v:
Journal of Clinical Oncology. 33:62-62
62 Background: MSI is prognostic for survival in diverse cancers and predicts resistance to fluoropyrimidine chemotherapy in colon cancer. We examined the interaction between MSI and patient (pt) characteristics and survival for pts randomised to sur